The intravenous administration of bevacizumab is used as an adjuvant therapy for many advanced cancers and has been associated with a significant reduction in the plasma VEGF level causing important adverse effects including hypertension, proteinuria, renal dysfunction,. Here, VEGFA is linked to Hypertension.